Drugs / LY2928057
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01991483 | Dec 2013 → Oct 2015 | chronic kidney disease | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01330953 | Mar → Sep 2011 | — | Eli Lilly and Company | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY2928057 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01330953 ↗ |
| Action | Inhibit | “LY2928057 bound ferroportin and blocked interactions with hepcidin, allowing iron efflux” PMID 30677788 ↗ Mar 2019 |
| Modality | Monoclonal antibody | “monoclonal antibodies, LY3113593 and LY2928057, targeting BMP6 and ferroportin respectively” PMID 30677788 ↗ Mar 2019 |
| Route | Intravenous | “single intravenous dose” NCT01330953 ↗ |